Your browser doesn't support javascript.
loading
Impact of type of oral anticoagulants in patients with cerebral microbleeds after atrial fibrillation-related ischemic stroke or TIA: Results of the NOACISP-LONGTERM registry.
Wagner, Benjamin; Hert, Lisa; Polymeris, Alexandros A; Schaedelin, Sabine; Lieb, Johanna M; Seiffge, David J; Traenka, Christopher; Thilemann, Sebastian; Fladt, Joachim; Altersberger, Valerian L; Zietz, Annaelle; Dittrich, Tolga D; Fisch, Urs; Gensicke, Henrik; De Marchis, Gian Marco; Bonati, Leo H; Lyrer, Philippe A; Engelter, Stefan T; Peters, Nils.
  • Wagner B; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Hert L; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Polymeris AA; Department of Intensive Care Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Schaedelin S; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Lieb JM; Clinical Trial Unit, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Seiffge DJ; Department of Diagnostic and Interventional Neuroradiology, Clinic for Radiology and Nuclear Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Traenka C; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Thilemann S; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Fladt J; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Altersberger VL; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter and Department of Clinical Research, University of Basel, Basel, Switzerland.
  • Zietz A; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Dittrich TD; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Fisch U; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Gensicke H; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • De Marchis GM; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Bonati LH; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Lyrer PA; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Engelter ST; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter and Department of Clinical Research, University of Basel, Basel, Switzerland.
  • Peters N; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Front Neurol ; 13: 964723, 2022.
Article en En | MEDLINE | ID: mdl-36203998
ABSTRACT

Background:

Cerebral microbleeds (CMBs) may have a differential impact on clinical outcome in stroke patients with atrial fibrillation (AF) treated with different types of oral anticoagulation (OAC).

Methods:

Observational single-center study on AF-stroke-patients treated with OAC. Magnetic-resonance-imaging was performed to assess CMBs. Outcome measures consisted of recurrent ischemic stroke (IS), intracranial hemorrhage (ICH), death, and their combined analysis. Functional disability was assessed by mRS. Using adjusted logistic regression and Cox proportional-hazards models, we assessed the association of the presence of CMBs and OAC type (vitamin K antagonists [VKAs] vs. direct oral anticoagulants [DOACs]) with clinical outcome.

Results:

Of 310 AF-stroke patients treated with OAC [DOACs n = 234 (75%); VKAs n = 76 (25%)], CMBs were present in 86 (28%) patients; of these, 66 (77%) received DOACs. In both groups, CMBs were associated with an increased risk for the composite

outcome:

VKAs HR 3.654 [1.614; 8.277]; p = 0.002; DOACs HR 2.230 [1.233; 4.034]; p = 0.008. Patients with CMBs had ~50% higher absolute rates of the composite outcome compared to the overall cohort, with a comparable ratio between treatment groups [VKAs 13/20(65%) vs. DOACs 19/66(29%); p < 0.01]. The VKA-group had a 2-fold higher IS [VKAs4 (20%) vs. DOACs6 (9%); p = 0.35] and a 10-fold higher ICH rate [VKAs 3 (15%) vs. DOACs 1 (1.5%); p = 0.038]. No significant interaction was observed between type of OAC and presence of CMBs. DOAC-patients showed a significantly better functional outcome (OR 0.40 [0.17; 0.94]; p = 0.04).

Conclusions:

In AF-stroke patients treated with OAC, the presence of CMBs was associated with an unfavorable composite outcome for both VKAs and DOACs, with a higher risk for recurrent IS than for ICH. Strokes were numerically higher under VKAs and increased in the presence of CMBs. Clinical trial registration http//www.clinicaltrials.gov, Unique identifier NCT03826927.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2022 Tipo del documento: Article